Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 19, 2014, 03:58:50 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 639438
  • Total Topics: 48539
  • Online Today: 218
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Anti-HIV gel for anal use  (Read 1113 times)

0 Members and 1 Guest are viewing this topic.

Offline Cosmicdancer

  • Member
  • Posts: 150
Anti-HIV gel for anal use
« on: April 08, 2013, 03:58:04 PM »
http://www.sciencedaily.com/releases/2013/04/130403200300.htm

Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex

Apr. 3, 2013 — A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. The study, led by researchers with the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), tested a reduced glycerin formulation of tenofovir gel, and has spurred the development of an expanded safety study of the gel, expected to launch later this year.

Rectal microbicides, gel-based antiretroviral products applied into the rectum with the use of an applicator, are being developed as an approach for preventing or reducing the sexual transmission of HIV from unprotected anal sex.Researchers are working on developing rectal-specific products as well as reformulations of vaginal products, specifically, tenofovir gel.

The study, known as MTN-007, was the first to evaluate tenofovir gel reformulated with less glycerin, a common additive found in many gel-like products, in the hopes of making it better suited for use in the rectum.It began in October 2010 and enrolled 65 men and women at three sites -- the University of Pittsburgh, University of Alabama at Birmingham and Fenway Health in Boston.

In MTN-007, study participants were randomly assigned to one of four study groups. Three of these groups were assigned to use one of the following products for a one-week period:a reduced glycerin formulation of tenofovir gel; a placebo gel containing no active ingredient; or a gel containing the spermicide nonoxynol-9.A fourth group did not use any gel but took part in all of the study-related procedures and tests, including physical and rectal exams.

Study results, preliminarily presented at a scientific meeting in 2012, indicated no significant differences in side effects among the three gel groups.Eighty percent of participants reported minor side effects related to the use of study products, and 18 percent reported moderate side effects.(Two study participants reported severe adverse events, but they were not related to use of the study
products.)Participants' adherence to the use of their assigned study products was high, with 94 percent using the products daily as directed.When asked about the likelihood that they would use the gel in the future, 87 percent of the participants who used the reformulated gel indicated they would likely use the gel again, compared to 93 percent of the placebo gel group, and 63 percent of the nonoxynol-9 gel group.In addition to assessing safety and acceptability, researchers also conducted gene expression testing, and noted changes in the activation of some genes in the reduced glycerin tenofovir gel group, which they will continue to assess in future rectal microbicide studies.

"We are very encouraged that the reformulated gel was quite safe, and that most people who used it said they would be willing to use it in the future," said Ian McGowan, M.D., Ph.D., co-principal investigator of the MTN and professor of medicine, Division of Gastroenterology, Hepatology and Nutrition and Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine."These results have formed the basis for a follow-up study that should provide us with even more detailed information about the safety and acceptability of the gel."

Researchers are now in the final planning stages of a Phase II, multi-site trial of the reformulated gel called MTN-017 that will involve 186 men who have sex with men and transgender women at clinical sites in Peru, South Africa, Thailand, and the U.S., including Puerto Rico.Participants will cycle through three study regimens:reformulated tenofovir gel used daily, reformulated tenofovir gel used before and after anal sex, and daily use of the antiretroviral tablet Truvada®.MTN-017 will allow researchers to collect additional information about the gel's safety and acceptability in the rectum, and compare it to the use of Truvada.

In addition to Dr. McGowan, other authors of the study include Craig Hoesley, M.D., University of Alabama; Ross Cranston, M.D., University of Pittsburgh; Philip Andrew, FHI 360; Laura Janocko, Ph.D., MTN and Magee-Womens Research Institute; James Dai, Fred Hutchinson Cancer Research Center; Alex Carballo-Dieguez, Ph.D., Columbia University; Ratiya Kunjara Na Ayudhya, BSMT, MTN; Jeanna Piper, M.D., Division of AIDS, National Institute of Allergy and Infectious Diseases; Florian Hladik, M.D., Ph.D., Fred Hutchinson Cancer Research Center; and Ken Mayer, M.D., Fenway Health.

MTN-007 was funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health, both components of the NIH.Tenofovir gel was developed by Gilead Sciences, Inc., of Foster City, Calif., which assigned the rights for tenofovir gel to CONRAD, of Arlington, Va., and the International Partnership for Microbicides of Silver Spring, Md., in December 2006.
CONRAD developed the reduced glycerin formulation of tenofovir gel evaluated in MTN-007 and it differs from the formulation originally developed for vaginal use.Although the vaginal gel produced a significant antiviral effect when used in the rectum, it was found to cause gastrointestinal side effects in some study participants in an earlier study called RMP-02/MTN-006.

The vaginal formulation of tenofovir gel continues to be evaluated for preventing the transmission of HIV through vaginal sex in women.Ongoing is a Phase III trial called FACTS 001 that is testing its use before and after sex among women in South Africa. FACTS 001 hopes to replicate the results of CAPRISA 004, which found this regimen reduced the risk of HIV by 39 percent compared to placebo gel. The VOICE Study (Vaginal and Oral Interventions to Control the Epidemic), however, found daily use of the gel not effective among its study participants; most of the women did not use the product daily as recommended.
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
June, 2008 - undetectable, 612 cd4
January, 2009 - undetectable, 670 cd4
May, 2009 - undetectable, 593 cd4
Sept, 2009 - 83 vl, 763 cd4, 34%
Dec, 2009 - undetectable, 889 cd4, 32%
April, 2010 - undetectable, 860 cd4, 31%
October, 2010 - undetectable, 800 cd4, 38%
April, 2011 - undetectable, t-cell test not done
October, 2011 - undetectable
April, 2012 - undetectable, 850 cd4, 39%
November, 2012 - undetectable, 901 cd4, 41%
April, 2013 - undetectable, 846 cd4, 36%
October, 2013 - undetectable
May, 2014 - undetectable, 784 cd4, 48%

Offline Matts

  • Member
  • Posts: 214
Re: Anti-HIV gel for anal use
« Reply #1 on: April 08, 2013, 04:06:49 PM »
Not bad:)

and not to forget EFda. It is 60,000 times more potent than current drugs and will be another good anal- and vaginal gel some day.

http://munews.missouri.edu/news-releases/2010/0125-new-compound-could-be-alternative-strategy-for-preventing-hiv-infection/

But now i have to have a minute's silence for Baroness Thatcher. :)
tivicay/kivexa

Offline Ann

  • Administrator
  • Member
  • Posts: 28,140
  • It just is, OK?
    • Num is sum qui mentiar tibi?
Re: Anti-HIV gel for anal use
« Reply #2 on: April 09, 2013, 06:30:12 AM »
It's great to know that someone is finally testing microbicides for anal use. It's about time! :)
Condoms are a girl's best friend

Condom and Lube Info  



"...health will finally be seen not as a blessing to be wished for, but as a human right to be fought for." Kofi Annan

Nymphomaniac: a woman as obsessed with sex as an average man. Mignon McLaughlin

HIV is certainly character-building. It's made me see all of the shallow things we cling to, like ego and vanity. Of course, I'd rather have a few more T-cells and a little less character. Randy Shilts

Offline emeraldize

  • Member
  • Posts: 3,348
Re: Anti-HIV gel for anal use
« Reply #3 on: April 09, 2013, 07:27:05 AM »
I believe such pursuits began with MTN-006 in 2009.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.